CSL and Alentis will work together to progress antifibrotic drug, lixudebart across multiple rare kidney and liver diseases.

AstraZeneca has opened a new global strategic R&D facility in Massachusetts, US, as part of an investment of more than $1bn in the state.

The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, as pharma explores its role on treating ophthalmic conditions.

The US FDA has expanded the approved indication for BMS' Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg.

Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours.

Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.

Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.

Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines.

Established CDMO Piramal Pharma Solutions is exhibiting at the forthcoming CPHI Milan 2026. The event will showcase the latest innovations in drug development, manufacturing, supply chains, and ...

Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their pipeline horizon – the companies have agreed to expand ...

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.